🇺🇸 FDA
Pipeline program

Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

BLU-263-1201

Phase 3 small_molecule active

Quick answer

Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB for Indolent Systemic Mastocytosis and SSM is a Phase 3 program (small_molecule) at Blueprint Medicines (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Blueprint Medicines (Netherlands) B.V.
Indication
Indolent Systemic Mastocytosis and SSM
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials